Updated Apr. 14, 2017 at 8:03 a.m.

Premium Lock Inside an IPO offering: G1 Therapeutics lays out its case for investors

Published: 2017-04-14 07:57:00
Updated: 2017-04-14 08:03:20

G1 targets cancer A graphic in G1's IPO filing explains in part how its technology works. Image 1 of 2 · Next Image…

G1 Therapeutics, which is seeking treatments for cancer, is looking to go public with an IPO valued at some $115 million. The startup, which is backed by serial biotech investor and entrepreneur Fred Eshelman, spells out reasons why it believes investors should be interested in its technology and potential products....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders